RVTY · Revvity Inc
Price
Snapshot
50 fields · last close| Market Cap | $14.58B |
| P/E | 61.02 |
| Float | 111.2M |
| Beta | 1.11 |
| Volatility | 27.7% |
| Exchange | NYSE |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 73 |
| Price | 130.71 |
| Change | +0.06% |
| Prev Close | 130.63 |
| Open | 132.45 |
| Day Low | 127.78 |
| Day High | 133.00 |
| Avg Vol | 2 |
| Avg $ Vol | $243.4M |
| 52W High | 131.75 |
| 52W Low | 81.22 |
| 52W Pos | 97.9% |
| From High | −0.79% |
| From Low | +60.93% |
| Max DD 1Y | −30.14% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +6.86% |
| SMA 50 | +12.62% |
| SMA 200 | +27.94% |
| RSI (14) | 68.6 |
| Vol 30D | 32.5% |
| Vol 90D | 39.2% |
| 1Y Range | 81–132 |
| Daily bars | 506 |
| Perf Week | +0.71% |
| Perf Month | +13.57% |
| Perf Quarter | +27.57% |
| Perf Half Y | +35.27% |
| Perf Year | +56.71% |
| Perf YTD | +33.17% |
| Prev Day | +0.06% |
| Clavix | B |
| Debt / Eq | 0.44 |
| Curr Ratio | 1.68 |
| Int Cover | 3.5× |
| FCF Margin | 21.1% |
| Rev Growth | +1.3% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 8 / 19 |
What RVTY does
Revvity, Inc. provides health sciences solutions, technologies, and services.
The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery.
It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names.
The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023.
Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Clavix risk grade
regraded every trading dayRVTY grades B, 73 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (57, mixed). 2 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 8 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| RVTY | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.11 | 1.19 |
| Volatilityannualized | 27.7% | 29.7% |
| Max drawdown, past yearworst peak-to-trough fall | −30.1% | — |
| Typical daily movemedian absolute daily change | 1.38% | — |
| Days beyond ±3%of the last 252 sessions | 5221% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| RVTY | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.11 | 1.19 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| RVTY | |
|---|---|
| 1 week | +0.7% |
| 1 month | +13.6% |
| Year to date | +33.2% |
| 1 year | +56.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| RVTY | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 20 Jul |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 0 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 0 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| RVTY | |
|---|---|
| Revenue growthyear over year | +1.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Life Sciences Tools & Services
19 companies| Metric | RVTY | Sector spread | Median |
|---|---|---|---|
| Beta | 1.11 | 1.19 | |
| Volatility | 27.7% | 29.7% | |
| P/E | 61.02 | 36.77 | |
| Debt / equity | 0.44 | 0.51 | |
| Current ratio | 1.68 | 1.89 | |
| FCF margin | 21.1% | 19.5% | |
| Interest coverage | 3.5× | 3.5× |
Recent news
most recent scored articles · the chip is the article’s score · click to openRevvity (RVTY) was upgraded to a Zacks Rank #2 (Buy) based on growing optimism about its earnings prospects, though the article provides no specific details about what is driving that optimism.
Sone Capital Management LLC disclosed in an SEC filing that it bought a new position in Revvity Inc. (RVTY) during the second quarter, acquiring 109,761 shares worth about $12.21 million. The article text is cut off and does not provide further detail.
Mitsubishi UFJ Asset Management bought a new position in Revvity Inc. (RVTY) during the second quarter, purchasing 148,853 shares according to its Form 13F filing with the SEC.
Revvity (RVTY) launched SuperFlex, a compact automated prenatal screening system targeted at smaller labs and clinics to enable rapid in-house testing.
Revvity has launched SuperFlex, a compact and automated prenatal screening system designed to give smaller labs and clinics the ability to run rapid prenatal tests in-house.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CRL | Charles River Laboratories International Inc | B- | $14.00B | — | 1.40 | Compare |
| MEDP | Medpace Holdings Inc | B- | $16.56B | 33.64 | 1.13 | Compare |
| TEM | Tempus AI Inc | D- | $11.67B | — | 2.34 | Compare |
| TECH | Bio-Techne Corp | B- | $11.36B | 62.34 | 1.30 | Compare |
| AVTR | Avantor Inc | B- | $10.27B | — | 0.98 | Compare |
| RGEN | Repligen Corp | B- | $9.57B | 229.65 | 1.14 | Compare |
| BRKR | Bruker Corp | C- | $9.05B | — | 1.25 | Compare |
| QGEN | Qiagen NV | B+ | $9.04B | 21.93 | 0.59 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.